ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) and the Duke Clinical Research Institute (DCRI) today announced the first enrollment in a major study designed to better understand appropriate anti-clotting medication therapies for patients following implantation of tissue heart valves.
